Detalles de la búsqueda
1.
Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
Klin Onkol
; 30(Supplementum2): 81-91, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28903575
2.
Biomarkers in Immunoglobulin Light Chain Amyloidosis.
Klin Onkol
; 30(Supplementum2): 60-67, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28903572
3.
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Ann Oncol
; 26(10): 2155-61, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26216382
4.
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leukemia
; 33(4): 969-980, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30315239
5.
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Leukemia
; 18(5): 989-97, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-14999298
6.
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.
Transplant Proc
; 37(10): 4482-7, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16387150
7.
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Med Oncol
; 18(2): 141-8, 2001.
Artículo
en Inglés
| MEDLINE | ID: mdl-11778760
8.
Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers.
Bone Marrow Transplant
; 48(7): 915-21, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23292239
9.
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Ann Hematol
; 84(9): 557-64, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15856358
10.
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Eur J Haematol
; 71(3): 155-62, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12930315
Resultados
1 -
10
de 10
1
Próxima >
>>